LENZ Therapeutics (NASDAQ:LENZ) Receives New Coverage from Analysts at William Blair

Investment analysts at William Blair began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set an “outperform” rating on the stock.

LENZ has been the subject of a number of other reports. Citigroup began coverage on shares of LENZ Therapeutics in a research note on Wednesday, April 10th. They set a “buy” rating and a $34.00 target price for the company. Piper Sandler began coverage on shares of LENZ Therapeutics in a research note on Wednesday, March 27th. They set an “overweight” rating and a $28.00 target price for the company.

LENZ Therapeutics Stock Down 2.5 %

NASDAQ LENZ opened at $19.92 on Monday. The firm has a market cap of $165.73 million, a price-to-earnings ratio of -1.28 and a beta of 0.20. LENZ Therapeutics has a 52 week low of $14.07 and a 52 week high of $29.82.

Insider Buying and Selling

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. acquired 998,009 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was bought at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the purchase, the director now directly owns 3,319,339 shares in the company, valued at $49,889,665.17. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 38.40% of the stock is owned by insiders.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.